Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 15/20 | 0.62 |
| ▸ | BLK | P51451 | 3/20 | 0.59 |
| ▸ | BMX | P51813 | 3/20 | 0.59 |
| ▸ | JAK3 | P52333 | 3/20 | 0.59 |
| ▸ | BTK | Q06187 | 3/20 | 0.59 |
| ▸ | TEC | P42680 | 1/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.56 |
| ▸ | NR2C2 | P49116 | 1/20 | 0.54 |
| ▸ | CLK1 | P49759 | 1/20 | 0.54 |
| ▸ | CLK2 | P49760 | 1/20 | 0.54 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.54 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6877149 | 0.89 | MTOR (0.80) | MTORPIK3CADYRK1ACLK1 | |
| SCHEMBL7919433 | 0.87 | PIK3CA (0.70) | MTORPIK3CA | |
| SCHEMBL7911947 | 0.86 | PIK3CA (0.73) | MTORBLKBMXJAK3BTK | |
| SCHEMBL6874999 | 0.86 | MTOR (0.80) | MTORBLKBMXJAK3BTK | |
| SCHEMBL6874084 | 0.84 | PIK3CA (0.73) | MTORBLKBMXJAK3BTK | |
| SCHEMBL7919485 | 0.81 | PIK3CA (0.77) | MTORBLKBMXJAK3BTK | |
| SCHEMBL20348941 | 0.80 | MTOR (0.55) | MTORPIK3CA | |
| SCHEMBL20834105 | 0.79 | MTOR (0.78) | MTORPIK3CADYRK1ACLK1 | |
| SCHEMBL6876324 | 0.79 | PIK3CA (0.72) | MTORBLKBMXJAK3BTK | |
| SCHEMBL11887277 | 0.78 | MTOR (0.62) | MTORPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889706-B2 | Soluble mTOR complexes and modulators thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889706-B2 | Soluble mTOR complexes and modulators thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140018354-A9 | INHIBITORS OF MTOR KINASE AS ANTI-VIRAL AGENTS | KADMON CORPORATION, LLC | 2014-01-16 | — | — | US | disclosed |
| US-20140018354-A9 | INHIBITORS OF MTOR KINASE AS ANTI-VIRAL AGENTS | KADMON CORPORATION, LLC | 2014-01-16 | — | — | US | disclosed |
| US-20130072485-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072485-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8394818-B2 | Soluble mTOR complexes and modulators thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394818-B2 | Soluble mTOR complexes and modulators thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120190676-A1 | INHIBITORS OF MTOR KINASE AS ANTI-VIRAL AGENTS | MOORMAN NATHANIEL (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190676-A1 | INHIBITORS OF MTOR KINASE AS ANTI-VIRAL AGENTS | MOORMAN NATHANIEL (US) | 2012-07-26 | — | — | US | disclosed |
| US-20110288091-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288091-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2011-11-24 | — | — | US | disclosed |
| WO-2010044885-A2 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190676-A1 | INHIBITORS OF MTOR KINASE AS ANTI-VIRAL AGENTS | EIF2AK2, MTOR, EIF4EBP1 | MTOR 2/4885BLK 1195/4885BMX 1318/4885 |
| US-20130072485-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | MTOR, RICTOR, RPTOR | MTOR 1/4885BLK 1714/4885BMX 1963/4885 |
| US-20140018354-A9 | INHIBITORS OF MTOR KINASE AS ANTI-VIRAL AGENTS | EIF2AK2, MTOR, EIF4EBP1 | MTOR 2/4885BLK 1195/4885BMX 1318/4885 |
| US-20110288091-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | MTOR, RICTOR, RPTOR | MTOR 1/4885BLK 1714/4885BMX 1963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.